Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB368 in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations

NCT07542704 is registered in ClinicalTrials.gov with Kumquat Biosciences Inc. as lead sponsor.

NCT NCT07542704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07542704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB368 in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations
Lead sponsor
Kumquat Biosciences Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
December 31, 2029
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal cancer (crc), kras g12c mutations, kras g12s mutations, non-small cell lung cancer, uterine cancer